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P rostate cancer (PCa) is diagnosed based on the measurement of the patient’s serum prostate-spe-
cific antigen (PSA) level and the results of a digital rec-
tal examination (DRE),  magnetic resonance imaging 
(MRI),  and prostate biopsy (PB).  In cases of metastatic 
PCa,  almost all patients are diagnosed based on the 
prostate biopsy results.  Cases of metastatic PCa that 
cannot be detected by prostate biopsy are extremely 
rare.
The term “burned-out prostate cancer” refers to a 
regressed PCa that is detected only because of the pres-
ence of metastases; that is,  the metastases persist but 
the primary tumor is undetectable.  There are very few 
reports of burned-out tumors in other cancers,  and to 
the best of our knowledge there are no reports of 
burned-out prostate cancer in the literature [1].  Here,  
we report a rare case of metastatic cancer likely origi-
nating from burned-out prostate cancer.
Case Report
A 51-year-old Japanese man visited a local orthope-
dic hospital with lumbar back pain.  The physical find-
ings and lumbar X-ray were normal.  The pain recurred 
2 months later,  and MRI revealed a metastatic tumor in 
the spine (Fig. 1A).  He was referred to our hospital,  
where a needle biopsy was performed by an orthope-
dist.  The histopathological findings indicated metastatic 
adenocarcinoma,  and immunohistochemical staining 
was positive for PSA (Fig. 2A , B).  As the primary origin 
of the bone metastasis was assumed to be the prostate,  
he was referred to our institution.  His serum PSA level 
was 13.64 ng/ml,  and the DRE revealed a soft prostate 
without hard nodules.  MRI showed enlarged obturator 
lymph nodes and a normal prostate without cancerous 
Acta Med.  Okayama,  2018
Vol.  72,  No.  6,  pp.  605-609
CopyrightⒸ 2018 by Okayama University Medical School.
http ://escholarship.lib.okayama-u.ac.jp/amo/Case Report
Burned-out Prostate Cancer ?  
Primary Metastatic Cancer Not Detected on Repeat Biopsy
Yosuke Mitsuia,  Takuya Sadahiraa＊,  Yuki Maruyamaa,  Koichiro Wadaa,   
Ryuta Tanimotoa,  Morito Sugimotoa,  Motoo Arakia,  Masami Watanabea,   
Hiroyuki Yanaib,  Toyohiko Watanabea,  and Yasutomo Nasua
Departments of aUrology and bPathology,  Okayama University Graduate School of Medicine,   
Dentistry and Pharmaceutical Sciences,  Okayama University Hospital,  Okayama 700-8558,  Japan
Metastatic prostate cancer (PCa) cases that cannot be detected on repeat prostate biopsy are extremely rare.  Our 
patient was a 51-year-old Japanese man diagnosed as metastatic PCa by histopathological examination of 
lesions obtained bone biopsy and lymph node dissection.  The primary tumor was not detected after repeated 
prostate biopsy.  Metastatic PCa was diagnosed based on immunohistochemical staining: PSA,  AR,  P504S,  
and NKX3.1 of bone and lymph node with metastasis.  We speculate that the primary PCa was “burned-out,” 
demonstrating remote metastases with no apparent primary tumor in the prostate.  Burned-out PCa may be 
difficult to diagnose and treat due to its rarity.
Key words:  prostate cancer,  metastasis,  unknown primary tumor,  repeat biopsy,  CRPC
Received January 19, 2018 ; accepted September 20, 2018.
＊Corresponding author. Phone : +81-86-231-7287; Fax : +81-86-231-3986
E-mail : t.sadahira@gmail.com (T. Sadahira)
Conflict of Interest Disclosures: No potential conflict of interest relevant 
to this article was reported.
lesions.
We next performed a 10-core transrectal prostate 
biopsy.  The biopsy findings did not identify malignant 
prostate lesions,  suggesting that the origin of the pri-
mary tumor was not the prostate.  A positron emission 
tomography (PET) study revealed elevated standard 
uptake values (SUVs) in the spine,  both obturator 
lymph nodes,  and the antrum of the stomach (Fig.1B-E).  
He underwent an esophagogastroduodenoscopy,  but no 
malignant findings were detected on stomach biopsy 
samples.  The patient subsequently underwent multiple 
prostate biopsies,  including a six-core transrectal pros-
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Fig. 1 A: MRI images showing bone metastases (arrows). PET revealed elevated SUVs in the spine (B ,D), antrum of the stomach (C), 
and right obturator lymph node (E).
Fig. 2 Immunohistochemical staining of the bone and lymph node metastases.  H&E staining in bone metastases.  A,  Inset is high magni-
ﬁcation; B,  PSA staining in bone metastases; C,  AR staining in bone metastases; D,  P504S staining in bone metastases; E,  H&E 
staining of lymph node; F,  NKX3.1 staining of lymph node.
tate biopsy and a 31-core transperineal-template pros-
tate biopsy,  but no malignant tissue was detected by 
hematoxylin and eosin (HE) stain.
Additional immunohistochemical staining of meta-
static tissue revealed positive androgen receptor (AR) 
and P504S staining (Fig. 2C , D).  The pathological diag-
nosis was thus determined to be prostate cancer.  We 
performed a laparoscopic lymph node dissection to rule 
out lymphoma and confirm the diagnosis.  The histo-
logical findings of the right obturator lymph node dis-
section confirmed moderately differentiated adenocar-
cinoma (Fig. 2E).  Immunohistochemical staining was 
positive for PSA and NKX3.1,  a marker of prostate 
cancer (Fig. 2F).  We diagnosed metastatic PCa,  and we 
administered combined androgen blockade (CAB) 
therapy including a luteinizing hormone-releasing hor-
mone (LH-RH) antagonist and an anti-androgen agent.
The patient’s PSA level was markedly decreased with 
this therapy; at 1,  2,  and 3 months after the comple-
tion of the CAB his serum PSA levels were 1.07 ng/ml,  
0.485 ng/ml,  and 0.327 ng/ml,  respectively.  At 4 months 
after the completion of the CAB,  the patient reported 
having a back ache (which was likely due to metastasis),  
and the metastatic lesion was shown by MRI to have 
extended slightly.  Radiation therapy at L5 was per-
formed to counteract the patient’s pain.
Discussion
Bone metastases are commonly encountered in clin-
ical settings,  with 7.8-21.7% originating from an 
unknown primary tumor [2].  In such cases,  the lungs 
and prostate are the most common sites of origin.  In a 
retrospective study,  286 cases of bone metastases with 
unknown primary tumors was observed in a group of 
2,641 patients with bone metastases [3].  Bone biopsies 
were performed in 141 of the 286 patients,  and 138 
biopsies (48%) had positive findings.  The origin was 
suspected to be the prostate in 23 (16.6%) of the 138 
cases.  All 23 cases had a positive prostate biopsy.  In our 
patient’s case,  however,  despite repeat prostate biopsies 
including saturation biopsies,  the primary tumor site 
could not be identified.
Immunohistochemical staining can help determine 
the origin of metastatic tumors.  For example,  the com-
bined expression patterns of CK7 and CK20 can suggest 
the primary site [4 , 5].  CK7 is found in a variety of 
cancers,  including lung,  breast,  thyroid,  pancreas,  
ovary,  and endometrium.  CK20 is expressed in gastro-
intestinal cancers and urothelial cancer.  Of note,  both 
CK7 and CK20 are negative in prostate cancer [5].  
Although the immunohistochemical staining of CK7/
CK20 is helpful in PCa,  it is not enough for a definitive 
diagnosis.  To confirm the diagnosis of PCa,  immuno-
histochemistry markers such as PSA or prostatic-spe-
cific acid phosphatase (PSAP) are used.  In poorly dif-
ferentiated prostate cancer,  PSA and PSAP may be 
focally or weakly expressed [6].  PSA and AR are not 
specific for PCa.  It was reported that PSA and AR were 
present in breast cancer and parotid cancer [7 , 8].  We 
had to rule out these cancers in our patient.
P504S (also known as α-methylacyl-CoA race-
mase: AMACR) and NKX3.1 were recently reported to 
be effective for diagnosing PCa with a needle biopsy 
[9 , 10].  To identify an unknown primary site,  it is 
important to combine immunohistochemical staining 
for several markers.  In the present case,  PSA and 
P504S were positive in the bone metastases,  and 
NKX3.1 was positive in the lymph node metastases.  
Despite the absence of malignancy on repeat prostate 
biopsy,  we were able to confirm the diagnosis of meta-
static PCa by combining specific immunohistochemis-
try markers from multiple sites.
An extended biopsy with 10-24 cores is the current 
gold standard for the initial prostate biopsy.   The cancer 
detection rate of 10-24 transrectal prostate biopsy 
(TRPB) cores is 20-40% [11].  The detection rate of 
transperineal prostate biopsy (TPPB) is superior to that 
of TRPB in the anterior peripheral zone or apex in cases 
with a large prostate volume,  but some studies observed 
no significant difference in cancer detection rates 
between TRPB and TPPB on initial biopsy [12].  In 
repeat biopsy settings,  35-68% of patients whose initial 
TRPB was negative could be diagnosed with the use of a 
40-70 core transperineal template biopsy [13].  In repeat 
saturation biopsies,  TRPB and TPPB have a similar PCa 
detection rate [14].  Combining TRPB with TPPB or a 
template-guided saturation biopsy may improve cancer 
detection [15].
The term “burned-out tumor” was first reported by 
Prim in 1927 regarding testicular cancer,  and only 80 
burned-out tumor cases have been reported in the liter-
ature [16].  Burned-out tumors make up approx.  1.0% 
of testicular germ cell tumors [17].  Primary tumor 
atrophy was observed in these cases,  but the size of the 
testis was unchanged.  It may thus be difficult to detect 
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burned-out tumors in clinical settings.  The mechanism 
of the burned-out phenomenon is not known,  but sev-
eral theories have been proposed.  For example,  it was 
suggested that the burned-out phenomenon represents 
a spontaneous regression of the primary tumor that 
occurs after metastasis in patients with germ cell tumors.  
Regression may be due to an immune response at the 
site of tumor origin or by ischemia caused by the high 
metabolic rate of a neoplasm that has outgrown its 
blood supply [18].
In our patient’s case,  several uncertainties remain.  
First,  it remains unclear whether the origin of the 
metastasis was the prostate.  The patient’s increased 
serum PSA level and the immunohistochemical staining 
of bone and lymph nodes were consistent with PCa.  In 
addition,  the PSA level was markedly decreased after 
CAB therapy.  Therefore,  the origin of the primary 
tumor was most likely the prostate.
Second,  it remains unclear why the prostate biopsy 
samples in our patient’s case did not reveal malignancy.  
In a previous case,  invasive PCa was detected as an 
occult cancer,  because the PCa lesion was small [19].  
For the detection of small PCa lesions,  it is essential to 
use a saturation biopsy technique such as TRPB or 
TPPB.  In the present case,  we performed a saturation 
biopsy using a combination of TRPB and TPPB with a 
template.  Although a third or fourth biopsy could have 
been performed,  the probability of detecting a malig-
nancy would be low.
The cancer detection rates reported for second 
through sixth biopsies were 17%,  14%,  11%,  9% and 
7%,  respectively [20].  In that report,  almost all of the 
prostate cancers were described as detected by the time 
of the second biopsy,  and when cancer was detected on 
the third biopsy or later,  the Gleason score was low and 
the pathological history was low-grade.  In our patient’s 
case,  no malignancy was identified on 37 cores of satu-
ration biopsy,  indicating the absence of a small invasive 
tumor.  For this reason,  we suspect that the primary 
prostate tumor was burned-out.  To the best of our 
knowledge,  only nine cases of metastatic PCa whose 
primary lesion could not be detected by repeat biopsy 
have been reported.  In one of these cases,  docetaxel-
based chemotherapy was begun but the patient soon 
showed resistance to the chemotherapy and died 21 
months after the initial prostate biopsy [21].
In our patient’s case,  the PSA level was low despite 
the presence of both bone and lymph node metastases.  
In addition,  at 51 years old the patient was much younger 
than typical PCa patients.  Atypical cases such as the 
present case should be followed closely with both PSA 
monitoring and imaging,  because these cases can 
develop into castration-resistant prostatic carcinoma 
(CRPC).  A recent report showed that a combination of 
docetaxel and androgen-deprivation therapy (ADT) for 
metastatic PCa resulted in significantly longer overall 
survival than ADT alone [22].  In light of that finding,  
we would have started docetaxel for our patient at the 
beginning of ADT.
In conclusion,  we have reported an extremely rare 
case of metastatic cancer likely originating from burned-
out prostate cancer.  Prostate cancer should be sus-
pected in cases of bone metastases with an unknown 
primary cancer,  and a bone biopsy is mandatory.  Based 
on the present experience,  it may be difficult to diag-
nose and start of primary treatment for metastatic pros-
tate cancer with an undetectable primary tumor,  in light 
of its rarity.
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